Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
21 Maio 2019 - 5:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced that Terry Rosen, Ph.D., Chief
Executive Officer, will present at the Jefferies 2019 Global
Healthcare Conference on Tuesday, June 4, 2019 at 4 pm ET at the
Grand Hyatt, in New York, NY.
To access the live audio webcast of the presentation, please
visit the “Investors” section of the Arcus website at
www.arcusbio.com. A replay of the webcast will be available for 30
days following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist AB928, which is in a
Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is in a Phase
1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small molecule inhibitor of CD73, which is in a
Phase 1 healthy volunteer study. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about
Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005716/en/
Katherine Bock(415) 533-5670kbock@arcusbio.com
Nicole Arndt(510) 284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024